Roche Launches New Elevidys Trial Aiming for European Approval in Duchenne Gene Therapy Race

Roche is initiating a pivotal Phase 3 trial for its Duchenne muscular dystrophy gene therapy, Elevidys (delandistrogene moxeparvovec), with the primary goal of securing regulatory approval in Europe. This follows Elevidys's conditional approval in the U.S., which was based on surrogate endpoints. The new trial will enroll a broader age range of boys (4-16) and focus on demonstrating clinically meaningful functional benefits, aiming to satisfy the rigorous standards of the European Medicines Agency (EMA). The development occurs amidst ongoing scrutiny of gene therapies regarding cost, manufacturing complexity, and long-term efficacy and safety. Success in this trial is crucial for Roche's global expansion and could set precedents for other gene therapies. The outcome will be closely monitored as a key indicator of gene therapy's future viability and accessibility in treating rare genetic disorders.